Free Newsletter
Off-label Provigil might be addictive
Remember all those scientists who admitted to Nature that they sometimes used Provigil--Cephalon's stay-awake drug for folks with sleep apnea/narcolepsy/shift work syndrome--to make them more productive? Well, they might want to turn their more-productive brains toward analyzing the potential risks.
A new study shows that Provigil isn't the benign little puppy it seemed to be. Word was, Provigil was less likely to be addictive than other stimulants because it doesn't boost dopamine levels. But researchers used PET scanning to find that, lo and behold, Provigil actually does raise dopamine levels. Not as much as amphetamines do, but as much as the ADHD stimulant Ritalin (methylphenidate) does.
Study author Nora Volkow, who's director of the National Institute on Drug Abuse, said she hopes this small study inspires others to dig deeper into the potential risks of using Provigil off-label. A risk-free drug to make people better, smarter, faster--"that is like fairy tales," she told the Associated Press. "We currently have nothing that has those benefits without side effects."
For its part, Cephalon said people shouldn't pop Provigil willy-nilly: Jeffry Vaught, chief scientific officer, called Provigil "a very serious medication for serious medical disease. This is for pathological sleep disruption, not for people who've stayed awake for 24 hours."
- read the USA Today story
- check out the article from the Associated Press
Related Articles:
Why not use drugs for brainpower?
Cephalon hikes prices to fight generic
Pros use pills to boost brainpower
Provigil - Top 10 Warnings and Recalls
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: